Value Proposition

SCI is actively commercializing both its proprietary human stem cell platform (PluriCells^TM) as well as its unique in vitro toxicology product suite (ACTIVTox^®/PREDICTIVTox^TM).

SCI offers industrial partners access to its high-end PluriCell platform through research partnerships and fee-for-service activities in its state-of-the-art facilities and collaborative risk-sharing projects.

SCI is also in the process of making its patented PluriCell lines, which are eligible for federal funding in the U.S., available to universities and other not-for-profit institutions to rapidly advance stem cell research.